| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
381,510,000 |
| Market
Cap: |
169.20(M) |
| Last
Volume: |
4,513,016 |
Avg
Vol: |
4,500,697 |
| 52
Week Range: |
$0.4435 - $2.04 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Agenus is a clinical-stage immuno-oncology (I-O) company engaged in the development of a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer and infections. Co.'s antibody candidates are balstilimab (an anti-PD-1 antibody) and zalifrelimab (an anti-CTLA-4 antibody), which are in Phase 2 trials as both a monotherapy (balstilimab) and combination therapy (balstilimab/zalifrelimab) for treatment of patients with second-line cervical cancer. Co. is also developing an anti-CTLA-4 antibody, botensilimab (also known as AGEN1181), which is designed to improve the magnitude of responses to first-generation anti-CTLA-4 molecules.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
500,000 |
525,000 |
525,000 |
| Total Buy Value |
$0 |
$324,050 |
$343,050 |
$343,050 |
| Total People Bought |
0 |
1 |
2 |
2 |
| Total Buy Transactions |
0 |
1 |
2 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Armen Garo H |
Chairman & CEO |
• – – |
2009-06-25 |
4 |
B |
$1.97 |
$49,250 |
D/D |
25,000 |
1,161,690 |
2.74 |
- |
|
| Wentworth Kerry |
VP, Clin., Reg. and Qual. |
• – – |
2009-06-25 |
4 |
S |
$1.97 |
$49,250 |
D/D |
(25,000) |
21,172 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• – – |
2009-06-01 |
4 |
A |
$0.66 |
$11,000 |
D/D |
16,591 |
1,136,690 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2009-05-01 |
4 |
A |
$0.60 |
$11,000 |
D/D |
18,245 |
1,120,099 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• – – |
2009-04-01 |
4 |
A |
$0.37 |
$11,000 |
D/D |
29,842 |
1,101,854 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• – – |
2009-03-02 |
4/A |
A |
$0.42 |
$11,000 |
D/D |
26,060 |
1,072,012 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• – – |
2009-03-02 |
4 |
A |
$0.42 |
$36,667 |
D/D |
86,867 |
1,132,819 |
|
- |
|
| Levitsky Hyam |
Director |
– • – |
2009-02-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,376 |
15,376 |
|
- |
|
| Hatsopoulos John |
Director |
– • – |
2009-02-25 |
4/A |
B |
$0.35 |
$6,912 |
D/D |
20,000 |
65,000 |
2.39 |
- |
|
| Hatsopoulos John |
Director |
– • – |
2009-02-25 |
4 |
B |
$0.37 |
$3,700 |
D/D |
10,000 |
55,000 |
2.31 |
- |
|
| Klaskin Christine M |
VP, Finance |
• – – |
2009-01-10 |
4 |
D |
$0.46 |
$2,965 |
D/D |
(6,446) |
28,457 |
|
- |
|
| Klaskin Christine M |
VP, Finance |
• – – |
2009-01-10 |
4 |
A |
$0.00 |
$0 |
D/D |
15,147 |
34,903 |
|
- |
|
| Wentworth Kerry |
VP Reg Aff and Clinical Ops |
• – – |
2009-01-10 |
4 |
D |
$0.46 |
$3,607 |
D/D |
(7,842) |
46,172 |
|
- |
|
| Wentworth Kerry |
VP Reg Aff and Clinical Ops |
• – – |
2009-01-10 |
4 |
A |
$0.00 |
$0 |
D/D |
24,017 |
54,014 |
|
- |
|
| Valentine Karen |
VP and General Counsel |
• – – |
2009-01-10 |
4 |
D |
$0.46 |
$2,859 |
D/D |
(6,215) |
34,674 |
|
- |
|
| Valentine Karen |
VP and General Counsel |
• – – |
2009-01-10 |
4 |
A |
$0.00 |
$0 |
D/D |
16,375 |
40,889 |
|
- |
|
| Sharp Shalini |
CFO |
• – – |
2009-01-10 |
4 |
A |
$0.00 |
$0 |
D/D |
26,201 |
90,091 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• – – |
2009-01-10 |
4 |
A |
$0.00 |
$0 |
D/D |
60,043 |
1,045,952 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• – – |
2009-01-05 |
4 |
A |
$0.00 |
$0 |
D/D |
68,750 |
985,909 |
|
- |
|
| Sharp Shalini |
CFO |
• – – |
2009-01-05 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
63,890 |
|
- |
|
| Valentine Karen |
VP and General Counsel |
• – – |
2009-01-05 |
4 |
D |
$0.48 |
$949 |
D/D |
(1,977) |
24,514 |
|
- |
|
| Valentine Karen |
VP and General Counsel |
• – – |
2009-01-05 |
4 |
A |
$0.00 |
$0 |
D/D |
5,209 |
26,491 |
|
- |
|
| Wentworth Kerry |
VP Reg Aff and Clinical Ops |
• – – |
2009-01-05 |
4 |
D |
$0.48 |
$1,239 |
D/D |
(2,582) |
29,997 |
|
- |
|
| Wentworth Kerry |
VP Reg Aff and Clinical Ops |
• – – |
2009-01-05 |
4 |
A |
$0.00 |
$0 |
D/D |
7,907 |
32,579 |
|
- |
|
| Klaskin Christine M |
VP, Finance |
• – – |
2009-01-05 |
4 |
D |
$0.48 |
$886 |
D/D |
(1,845) |
19,756 |
|
- |
|
536 Records found
|
|
Page 19 of 22 |
|
|
